JP Morgan Maintains Overweight on Beam Therapeutics, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Overweight rating on Beam Therapeutics (NASDAQ:BEAM) and raises the price target from $45 to $48.
August 07, 2024 | 5:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Eric Joseph maintains an Overweight rating on Beam Therapeutics and raises the price target from $45 to $48.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to boost investor confidence and positively impact Beam Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100